|
|
Article: DURAMED AND SCHEIN SIGN LETTER OF INTENT FOR CONJUGATED ESTROGENS DEVELOPMENT
- Article from:
- PR Newswire
- Article date:
- March 2, 1992
CopyrightCOPYRIGHT 1992 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
DURAMED AND SCHEIN SIGN LETTER OF INTENT FOR
CONJUGATED ESTROGENS DEVELOPMENT
CINCINNATI, March 2 /PRNewswire/ -- E. Thomas Arington, chairman and president of Duramed Pharmaceuticals, Inc., and Martin Sperber, chairman of Schein Pharmaceutical Inc., today announced the signing of an agreement in principle for the development, manufacturing and marketing of a new formulation of Conjugated Estrogens Tablets, the generic equivalent to the brand product Premarin. This new formulation will be designed to meet bioequivalence guidance established by the FDA in late 1991.
Under the agreement, Schein will provide project funding and technical ...